We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood-Based Method Tracks Gene Activity in the Living Brain

By LabMedica International staff writers
Posted on 04 Jun 2026

Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. More...

Tracking active genes could reveal how the body responds to environmental factors, medication, or disease progression, but current workflows rely on end-point analyses that miss in vivo dynamics. Researchers have now developed a blood-based approach for monitoring targeted gene transcription in living brain tissue.

Rice University (Houston, TX, USA) bioengineers have developed In-vivo Tracking of Active Transcription (INTACT), a method designed to monitor selected genes in living tissue using a standard blood draw. The approach aims to quantify transcriptional activity without removing or damaging tissue. The team describes this as a demonstration of nondestructive gene transcription measurement in the living brain.

INTACT integrates engineered reporter molecules, termed Released Markers of Activity (RMAs), with intracellular sensors that recognize a target messenger RNA (mRNA). Upon detecting the target mRNA, the sensors trigger production and release of RMAs into the bloodstream. The circulating RMAs can then be measured from blood, enabling longitudinal tracking of specific gene activity. Because the targeting sequence is encoded in the genetic construct, the system is presented as programmable for different genes.

The platform was validated in an animal model and was able to track transcriptional activity from three distinct brain regions simultaneously. The authors note that, unlike next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR), which require destruction of the analyzed sample, the new method permits repeated measurements over time in the same organism. The capability to multiplex by gene, neural circuit, or brain region is identified as an area for further development.

The study, “Monitoring in vivo transcription with synthetic serum markers,” was published in Nature Communications on May 27, 2026. The researchers also indicate potential to expand beyond the central nervous system, suggesting applicability to other tissues. They further state that the method is scalable and, in theory, adaptable to any gene sequence included in the construct.

“This is the first demonstration of measuring transcription for targeted genes nondestructively in living tissue. That means that we can actually select which gene we want to study and then see how it expresses over time within the same organism. That allows us to see what happens before, for example, a disease occurs and how gene expression changes as that disease progresses,” said Jerzy Szablowski, assistant professor of bioengineering at Rice and the corresponding author on a study.

Related Links
Rice University


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The SimpleScreen CRC platform uses multiomics, AI, and machine learning to analyze blood-based signals and detect cancer-associated patterns (Photo courtesy of Freenome)

Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions

Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.